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Abstract
Background: Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the
treatment of prostate cancer. As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced
in patients with hepatic or renal impairment, leading to greater drug exposure.
Methods: Open-label studies investigated the PK and tolerability of zibotentan in subjects with hepatic or renal
impairment, compared with those with normal organ function. In the hepatic and renal studies, respectively,
subjects were divided into categories using Child-Pugh classification or 24-hour urine creatinine clearance (mild,
moderate, or severe impairment and normal function). Each subject received a single oral dose of zibotentan 10
mg and PK sampling was undertaken. Within the hepatic study, AUC and Cmax were expressed as the ratio of
geometric means and 90% CI for each impairment group compared with the normal function group. The
possibility that hepatic impairment had a clinically relevant effect on exposure was considered if the upper 90% CI
for the ratio exceeded 2. In the renal study, AUC, Cmax and t1/2 were analyzed using linear regression fitting effects
for creatinine clearance and age.
Results: In the hepatic and renal studies respectively, 32 subjects (eight per group) and 48 subjects received
treatment (n = 18 normal, n = 12 mild, n = 9 moderate, n = 9 severe). Zibotentan Cmax was not significantly
affected by hepatic or renal impairment. Compared with the normal function group, zibotentan AUC was 40%
(1.40; 90% CI 0.91-2.17), 45% (1.45; 90% CI 0.94-2.24) and 190% (2.90; 90% CI 1.88-4.49) higher in subjects with mild,
moderate and severe hepatic impairment, respectively, and 66% (1.66; 90% CI 1.38-1.99), 89% (1.89; 90% CI 1.50-
2.39) and 117% (2.17; 90% CI 1.64-2.86) higher in subjects with mild, moderate and severe renal impairment,
respectively. In both studies mean t1/2 increased and zibotentan clearance decreased with the degree of
impairment. Headache was the most common AE in all groups.
Conclusions: Zibotentan absorption was unchanged, however, exposure was higher in subjects with hepatic or
renal impairment due to slower clearance. This increased exposure did not result in differences in the range or
severity of AEs observed.
Trial Registration: ClinicalTrials.gov: NCT00672581 and AstraZeneca study number D4320C00016 (renal trial;
conducted in Germany).
Background
Prostate cancer is a leading cause of death in men in the
Western world, accounting for an estimated 28% of new
cancer cases in men in the US in 2010 [1]. Patients with
advanced prostate cancer are initially treated with andro-
gen deprivation therapy; however, disease progression will
eventually occur in many men despite castrate serum
androgen levels. This stage of disease is defined as castra-
tion-resistant prostate cancer (CRPC) for which treatment
is currently limited to further hormonal manipulation or
cytotoxic chemotherapy [2].
The endothelin (ET) axis has been implicated in several
mechanisms that promote cancer progression. Endothe-
lin-1 (ET-1) acting through the endothelin A (ETA) * Correspondence: helen.tomkinson@astrazeneca.com
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angiogenesis, migration and invasion, as well as inhibiting
apoptosis [3]. Conversely, activation of the ETB receptor
by ET-1 promotes apoptosis and inhibits ET-1 produc-
tion [4,5]. In prostate cancer, increased expression of the
ETA receptor correlates significantly with increased
tumour stage and aggressiveness whilst ETB receptor
expression appears to be reduced or absent in CRPC [6].
Furthermore, activation of the ETA receptor by ET-1 is
thought to be a key factor driving bone metastasis, which
is a marked feature of CRPC [7,8]. In addition to its pro-
minent role in CRPC, the ET axis has recently been
implicated in a number of female malignancies including
gynecological and breast cancers [9].
Zibotentan (ZD4054) is an oral specific ETA receptor
antagonist in clinical development for the treatment of
CRPC. A Phase II study of zibotentan monotherapy
demonstrated a good tolerability profile and a promising
overall survival signal in patients with metastatic CRPC
who were pain free or mildly symptomatic for pain [10].
Zibotentan is being further assessed in a large Phase III
clinical trial programme in this disease setting [11,12].
Preclinical investigations of zibotentan in other tumour
types, including ovarian cancer, are ongoing [13,14].
Zibotentan exposure exhibited a dose-linear increase
between 5 and 15 mg doses in Caucasian patients with
CRPC. Following repeated dosing of zibotentan, there
was minimal accumulation and no temporal change in
the pharmacokinetics of zibotentan [15]. A pharmacoki-
netic (PK), metabolism and disposition study using [
14C]-
zibotentan has demonstrated that both renal excretion
and metabolism are important clearance mechanisms for
zibotentan [16]. The drug and its metabolites are predo-
minantly eliminated in urine with ~58% of parent com-
pound being eliminated by renal clearance. Metabolism
of zibotentan is known to be mediated by the CYP3A4
isozyme [16,17]. When zibotentan was administered in
combination with the potent inhibitor of CYP3A4, itraco-
nazole, exposure evaluated by the area under the plasma
concentration time curve from time zero to infinity
(AUC) was increased by 28% [17]. Therefore, patients
with hepatic or renal impairment may have reduced drug
clearance which could potentially lead to a greater expo-
sure to zibotentan than in patients with normal organ
function.
Many patients with CRPC have acute renal failure due
to obstruction of the urinary outflow tracts by the prostate
tumour [18]. Furthermore, chemotherapy and some
bisphosphonates, such as zoledronic acid, which are used
widely in this disease setting, have also been associated
with the development and progression of renal failure
[19,20]. As zibotentan may be given to patients with
CRPC prior to, or in conjunction with, chemotherapy and/
or bisphosphonates it is important to establish whether the
presence of hepatic or renal impairment has any impact
on its exposure.
T h ea i mo ft h et w os t u d i e sp r e s e n t e dh e r ew a st o
determine whether hepatic or renal impairment (in sub-
jects without CRPC) has any clinically relevant effect on
exposure to zibotentan by assessment of PK, safety and
tolerability parameters.
Methods
Study design and participants
Hepatic impairment study
This was an open-label, two-centre, single-dose, parallel-
group study which assessed the effect of mild, moderate
and severe hepatic impairment on the PK, safety and toler-
ability profile of zibotentan 10 mg. Subjects were divided
into four groups (n = 8 per group [n ≥ 2 subjects of each
sex per group]) using the Child-Pugh classification of hepa-
tic impairment [21] based on scores for encephalopathy,
ascites, serum bilirubin, serum albumin and prothrombin
time (Table 1): normal hepatic function, matched to the
hepatically impaired subjects with respect to age, gender
and weight (control); mild hepatic impairment (Child-Pugh
A); moderate hepatic impairment (Child-Pugh B); severe
hepatic impairment (Child-Pugh C).
Male and female subjects aged 18-75 years with a BMI
of 18-34 kg/m
2 were included in the study. Subjects with
normal hepatic function were required to be hepatitis B
and C negative and have normal values for clinical
laboratory tests and a normal medical history and exami-
nation. Females were to be surgically sterile or postmeno-
pausal. Hepatically impaired subjects were required to
have stable liver cirrhosis and hepatic impairment for at
least 3 months prior to screening. Subjects were excluded
if they had taken drugs with known significant cyto-
chrome P450 (CYP) inducer/inhibitory effects within
30 days prior to zibotentan dosing; had abnormal resting
Table 1 Child-Pugh classification of hepatic impairment
Points scored for observed findings
1 point 2 points 3 points
Encephalopathy grade* Absent 1 or 2 3 or 4
Ascites Absent Slight Moderate
Serum bilirubin (μmol/L) <34.2 34.2-51.3 >51.3
Serum albumin (g/L) >35 28-35 <28
Prothrombin time (INR) <1.16 1.16-1.56 >1.56
Classification
Child-Pugh grade Child-Pugh A Child-Pugh B Child-Pugh C
Points required 5-6 7-9 10-15
INR, international normalized ratio. *Encephalopathy: Grade 0: normal
consciousness, personality, neurological examination, electroencephalogram.
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired
handwriting, 5 cps waves. Grade 2: lethargic, time disorientated, inappropriate,
asterixis, ataxia, slow triphasic waves. Grade 3: somnolent, stuporous, place
disorientated, hyperactive reflexes, rigidity, slower waves. Grade 4: unrousable
coma, no personality/behaviour, decerebrate, slow 2-3 cps delta activity.
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Page 2 of 11vital signs of supine blood pressure >160 mmHg or <90
mmHg systolic or >95 mmHg or <50 mmHg diastolic or
supine pulse ≥100 beats per minute (bpm) or ≤40 bpm;
had a history or presence of gastrointestinal or renal dis-
ease or other condition known to interfere with the PK
profile of drugs. Subjects were excluded from the control
group if they had a history or presence of hepatic disease.
Exclusion criteria from the hepatically impaired groups
included: fluctuating or rapidly deteriorating hepatic
function or presence of a hepatocellular carcinoma or an
acute liver disease caused by drug toxicity or by an infec-
tion, significant renal dysfunction (creatinine clearance
below 50 mL/min), severe portal hypertension (with
exception of subjects in Child-Pugh C class) or surgical
porto-systemic shunts, presence of severe hepatic ence-
phalopathy, refractory ascites, or a platelet count below
40 × 10
9/L and/or neutrophil count <1.5 × 10
9/L and/or
hemoglobin <90 g/L.
Renal impairment study
This was an open-label, single-centre, single-dose study
which evaluated the effect of varying degrees of renal
impairment on the PK, safety and tolerability profile of
zibotentan 10 mg. Subjects were divided into four groups
at screening (n = 12 per group [n ≥ 2 subjects of each sex
per group, 50% of each group were to be >50 years])
using estimated creatinine clearance (CLCR) values (esti-
mated using the Cockcroft-Gault equation) [22]; normal
renal function (>80 mL/min); mild renal impairment
(≥50 to ≤80 mL/min); moderate renal impairment (≥30
to <50 mL/min); severe renal impairment (<30 mL/min).
Prior to analyzing the data, subjects were re-classified
into their appropriate renal impairment groups based
upon their measured creatinine clearance value deter-
mined using 24-hour urine collections on day -1 and
serum creatinine levels obtained pre-dose on day 1.
Male and female subjects aged 25-75 years with a BMI
of 18-32 kg/m
2 were included in the study. All subjects
were required to be hepatitis B and C negative and all
females were required to be surgically sterile or postmeno-
pausal. Subjects with normal renal function were required
to have normal values for clinical laboratory tests and a
normal medical history and examination. Renally impaired
subjects were to have had stable renal impairment for at
least 2 months prior to zibotentan dosing. Subjects were
excluded if they had taken drugs with known significant
CYP inducer/inhibitory effects within 30 days prior to
zibotentan dosing, had a history or presence of gastroin-
testinal or hepatic disease or other condition known to
interfere with the PK of drugs. Subjects were excluded
from the control group if they had a history or presence of
renal disease, had abnormal resting vital signs of supine
blood pressure >160 mmHg systolic or >100 mmHg dia-
stolic or supine heart rate ≥90 bpm or ≤50 bpm. Exclusion
criteria for renally impaired subjects included: renal
transplant and end stage renal disease patients, use of
drugs that affect creatinine clearance (such as cephalos-
porin antibiotics, ascorbic acid, trimethoprim, cimetidine
and quinine) within 8 days of dosing and abnormal resting
vital signs of supine blood pressure >180 mmHg or <110
mmHg systolic or >110 mmHg or <65 mmHg diastolic or
supine heart rate ≥90 bpm or ≤50 bpm.
In both studies, all subjects received a single oral dose
of zibotentan 10 mg and remained resident at the study
unit from the night before the zibotentan dose was
administered until 48 hours post dose.
The design of both trials followed the Food and Drug
Administration (FDA) [23,24] and the European regula-
tions [25,26] on the design and conduct of in vivo hepa-
tic or renal impairment studies. These studies were
performed in accordance with the Declaration of Hel-
sinki [27], consistent with the ethical principles of the
International Conference on Harmonization/Good Clini-
cal Practice [28]. The hepatic study was approved by the
Ethics Committee of the Institute for Clinical and
Experimental Medicine and Faculty Thomayer Hospital,
Prague, Czech Republic and the renal study was
approved by the Bavarian Physicians Board, Ethics Com-
mittee, Munich, Germany. All subjects provided written
informed consent prior to enrolment in the study and
subsequent screening.
Study objectives
The primary objective of these studies was to investigate
the PK of a single oral dose of zibotentan 10 mg in sub-
jects with hepatic or renal impairment compared with
healthy subjects. The secondary objectives were to assess
t h es a f e t ya n dt o l e r a b i l i t yo fas i n g l eo r a ld o s eo fz i b o -
tentan 10 mg in these subjects.
Procedures
Blood samples were collected for the determination of
plasma concentrations of zibotentan pre dosing and at
pre-defined intervals up to 96 and 120 hours, following
receipt of a single oral dose of zibotentan 10 mg for
subjects in the renal and hepatic impairment studies,
respectively. Blood samples were centrifuged at 4°C for
10 minutes at 1500g to provide plasma. An additional
blood sample was taken at 3 hours post dose for the
determination of protein binding of zibotentan and was
c e n t r i f u g e da t3 7 ° Cf o r1 0m i na t1 5 0 0 g to provide
plasma. Plasma samples were transferred into Amicon
Centrifree cartridges (30,000 molecular cut off; Milli-
pore, Watford). The cartridges were centrifuged in a
fixed angle rotor at 1000-2000g at 37°C for 30 minutes
to produce plasma ultrafiltrate. The collection cup was
removed and stored at -20°C. In the renal impairment
study, urine samples were collected from 0-6, 6-12, 12-
24, 24-36 and 36-48 hours post dosing for the
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volume of each urine collection was recorded.
Plasma, plasma ultrafiltrate and urine samples for zibo-
tentan analysis were stored at -20°C and transported to
York Bioanalytical Solutions Ltd (York, UK). Zibotentan
plasma and plasma ultrafiltrate concentrations were
determined as described previously [17]. An additional
calibration curve ranging from 5 to 5000 ng/mL which
used an internal standard concentration of 10,000 ng/mL
in water (rather than the 100 ng/mL solution previously
reported for the 0.5 to 500 ng/mL calibration range) was
used for plasma samples in the renal study and for
plasma ultrafiltrate samples. The performance of the
assay was monitored during each run using quality con-
trol samples at concentrations of 1.5, 200, 400 and 800
ng/mL where sample dilution was required (for the 0.5 to
500 ng/mL range) and 15, 2000 and 4000 ng/mL (for the
5 to 5000 ng/mL range) spiked into control human
plasma samples or into control human plasma ultrafil-
trate samples for the ultrafiltrate analysis. These were
prepared prior to commencement of the analysis of study
samples and stored at -20°C until required. In the hepatic
study the CV of the assay was ≤12% at all concentrations
and accuracy was typically between 98 and 103%. In the
renal study the CV of the assay was ≤9.3% and the accu-
racy was typically 96 and 103%. Following analysis of the
plasma ultrafiltrate samples, the CV of the assay was
≤8.4% in the hepatic study and ≤7% in the renal study
and accuracy ranged from 101 to 106% and 97.8 to 107%
for the hepatic and renal studies, respectively. Zibotentan
urine sample concentrations were determined by dilution
followed by HPLC with mass spectrometric detection
(HPLC-MS-MS). Urine samples were aliquoted (100 μL)
into polypropylene tubes with acetonitrile (100 μL). Sam-
ples were vortex mixed and sonicated at 40°C for 30 min-
utes. A 25 μL portion of each sample was aliquoted into a
2 mL square well plate and internal standard (900 μL,
1400 ng/mL) was added to each sample, except appropri-
ate blanks, to which mobile phase (900 μL) was added.
The plate was vortex mixed and centrifuged (3 minutes,
2500 rpm, 20°C), prior to being submitted for HPLC-
MS-MS analysis as previously described [17]. The CV of
the assay was ≤7.2% and the accuracy typically ranged
from 101 to 107%.
Zibotentan PK parameters determined included maxi-
mum plasma concentration (Cmax), time to Cmax (tmax),
area under the concentration-time curve from zero to
infinity (AUC), area under the concentration-time curve
from zero until the last measurable concentration
(AUC0-t), terminal half-life (t1/2), total apparent plasma
clearance (CL/F), apparent volume of distribution at
steady state (Vss/F), ratio of unbound drug in plasma
(Fu), free Cmax,f r e eA U C ,a n du n b o u n dC L / F .R e n a l
clearance (CLR)a n dt h ef r a c t i o no fd o s ee x c r e t e d
unchanged (Fe) were evaluated in the renal study only.
Non-compartmental methods were used for the evalua-
tion of the plasma concentration-time data and Cmax and
tmax were determined by inspection of the concentration-
time profiles. Where possible, the terminal elimination
rate constant (lz) was calculated by log-linear regression
of the terminal portion of the concentration-time pro-
files, and t1/2 was calculated as Ln2/lz. AUC0-t was deter-
mined using the linear trapezoidal rule, and where
appropriate, the AUC0-t was extrapolated to infinity
using l to obtain AUC. CL/F was calculated from the
ratio of dose/AUC and Vss/F was determined from the
mean residence time (MRT) × CL/F. The percentage of
free zibotentan was determined by comparison of the
free and total zibotentan concentrations at 3 hours post
dose; free Cmax and free AUC were calculated using Cmax
or AUC x percentage free zibotentan, respectively, and
unbound CL/F was determined by CL/F/percentage free
zibotentan. The amount of zibotentan excreted in the
urine was determined from the concentration of ziboten-
tan in each collection and the volume of urine collected.
CLR of zibotentan was calculated from the total amount
of zibotentan excreted/plasma AUC and the Fe of zibo-
tentan was calculated as the total drug excreted
unchanged/dose. The methods for the PK parameter
assessments and calculations reported in this study have
been described previously [29]. AUC, free AUC, AUC0-t,
Cmax,a n df r e eC max were presented as geometric mean
(CV) for each hepatic or renal study group. CL/F,
unbound CL/F, t1/2, Vss/F, CLR,F ea n dF uw e r ep r e -
sented as arithmetic mean (± standard error [SE]).
Safety and tolerability was evaluated by recording the
incidence of adverse events (AEs) according to Medical
Dictionary for Regulatory Activities (MedDRA) vocabu-
lary and the Common Terminology Criteria for Adverse
Events (CTCAE) Version 3, laboratory tests (hematol-
ogy, urinalysis and clinical chemistry), physical examina-
tion, and measurement of vital signs.
Statistical methods
In the hepatic impairment study AUC and Cmax were
logarithmically transformed using natural logarithms
(back-transformed results were reported). These para-
meters were analyzed using an analysis of variance model
(ANOVA) with a factor fitting for hepatic impairment
status (mild/moderate/severe or normal). Ratios of geo-
metric means of each hepatically impaired group com-
pared to the normal function group (mild/moderate/
severe: control) and 90% confidence intervals (CIs) were
reported. An effect of hepatic impairment was predefined
to have occurred if the upper 90% CI for the ratio did not
lie below 2. This was chosen as zibotentan 15 mg has
previously been tolerated in patients with CRPC; how-
ever, zibotentan 22.5 mg was not tolerated, therefore
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[30].
For the renal impairment study, statistical analysis of
AUC, Cmax (using natural logarithm transformed data)
and t1/2 (using untransformed data) was performed
using linear regression fitting effects for creatinine clear-
ance and age as explanatory variables. The slope para-
meter and corresponding SE were used to provide point
estimates and 90% confidence intervals (CIs) for the
ratio (or difference for t1/2) of zibotentan exposures in
subjects with severe, moderate and mild renal impair-
ment compared to subjects with normal renal function.
Results
Patient demographics
Thirty-seven subjects were enrolled in the hepatic impair-
ment study, 32 of whom received zibotentan and com-
pleted the study. In the renal impairment study, 52
subjects were enrolled and 48 subjects received zibotentan
and completed the study. Twenty-four hour urine collec-
tions could not be taken until subjects had given consent
and were admitted to the investigational site, therefore
estimated creatinine clearance values using the Cockcroft-
Gault equation were used at screening to classify subjects
with varying degrees of renal impairment, to achieve 12
subjects per group. Subjects were subsequently re-classi-
fied within the renal impairment categories according to
their actual serum creatinine clearance values obtained on
day 1, resulting in a disproportionate number of subjects
within each category. In both studies, all subjects were
Caucasian, cohorts were balanced with respect to age and
there were more males than females (Table 2).
Pharmacokinetics
Hepatic impairment study
The PK parameters and plasma concentrations of zibo-
tentan 10 mg in subjects with varying degrees of hepatic
impairment are presented in Table 3 and Figure 1a,
respectively. The results of the statistical analysis are
presented in Table 4 and Figure 2. Following a single
oral dose of zibotentan 10 mg, Cmax was unchanged in
subjects with mild, moderate and severe hepatic impair-
ment compared with those with normal hepatic function
(Table 4). Exposure in terms of AUC was significantly
Table 2 Demographic and baseline characteristics for subjects in the hepatic and renal impairment studies
Degree of hepatic impairment Degree of renal impairment
Normal hepatic
function (n = 8)
Mild
(n = 8)
Moderate
(n = 8)
Severe
(n = 8)
Normal renal
function (n = 18)
Mild
(n = 12)
Moderate
(n = 9)
Severe
(n = 9)
Male, n (%) 5 (63) 6 (75) 5 (63) 5 (63) 13 (72) 9 (75) 7 (78) 7 (78)
Female, n (%) 3 (38) 2 (25) 3 (38) 3 (38) 5 (28) 3 (25) 2 (22) 2 (22)
Mean age,
years (range)
58.4 (55-62) 56 (45-63) 59.3 (49-68) 52 (37-67) 60 (47-71) 58 (38-71) 60 (48-69) 57 (32-69)
Table 3 Pharmacokinetic parameters of zibotentan in subjects with normal renal function and varying degrees of
renal impairment, normal hepatic function and varying degrees of hepatic impairment
Degree of hepatic impairment Degree of renal impairment
PK parameter Normal hepatic
function (n = 8)
Mild
(n = 8)
Moderate
(n = 8)
Severe
(n = 8)
Normal renal
function (n = 18)
Mild
(n = 12)
Moderate
(n = 9)
Severe
(n = 9)
AUC(0-t) (ng·h/mL)* 5460 (46.2) 7560 (65.1) 7850 (50.3) 15100 (49.8) 5560 (36.9) 6910 (57.5) 9090 (35.2) 9640 (37.7)
AUC (ng·h/mL)* 5480 (46.0) 7680 (68.8) 7940 (50.7) 15900 (52.9) 5490 (39.0)
$ 6950 (58.3) 8710 (3.8)
£ 9750 (38.8)
Cmax (ng/mL)* 566 (25.6) 526 (22.3) 505 (23.0) 536 (30.2) 545 (22.7) 531 (28.8) 550 (9.9) 619 (20.6)
tmax (h)
† 2 (1-2) 2 (1-4) 2 (1-6) 2 (1-4) 1 (1-3) 1 (1-4) 2 (1-8) 1 (1-3)
t1/2 (h)
‡ 9.3 (3.6) 13.0 (9.4) 14.6 (6.5) 24.8 (10.9) 10.8 (2.7)
$ 11.3 (4.0) 13.5 (4.3)
£ 13.2 (4.7)
CL/F (mL/min)
‡ 33.2 (15.6) 25.0 (12.1) 23.6 (14.2) 11.9 (7.3) 32.7 (14.2)
$ 27.9 (18.9) 20.1 (6.5)
£ 18.2 (6.5)
Vss/F (L)
‡ 19.0 (6.1) 19.8 (3.1) 21.2 (7.2) 21.9 (7.1) 22.6 (7.0)
$ 20.8 (5.8) 19.3 (2.0)
£ 17.8 (3.4)
Fu (%)
‡ 22.5 (7.5) 23.4 (4.0) 20.2 (4.8) 29.2 (9.4) 22.8 (6.2) 25.4 (6.7) 26.6 (2.9) 27.9 (5.3)
CLR (mL/min)
‡ - - - - 17.4 (13.9)
$ 10.3 (16.8) 3.2 (5.6)
£ 2.3 (2.7)
£
Fe (%)
‡ - - - - 47.2 (18.0) 27.1 (19.5) 12.7 (16.9) 10.5 (9.0)
£
Free Cmax (ng/mL)* 121 (58.7) 123 (21.9) 97.3 (32.4) 149.2 (52.6) 121 (32.3) 131 (22.9) 145 (13.4) 170 (18.2)
Free AUC (ng·h/mL)* 1170 (69.3) 1800 (54.7) 1460 (56.5) 4430 (40.0) 1230 (39.1)
$ 1720 (60.6) 2260 (34.5)
£ 2680 (38.9)
Unbound CL/F (mL/min)
‡ 167 (98.4) 103 (46.8) 129 (69.8) 40 (14.7) 146 (67.3)
$ 115 (83.8) 77.4 (24.1)
£ 65.8 (22.3)
*Geometric mean (coefficient of variation, %),
†median (range),
‡arithmetic mean (standard deviation),
$n = 16,
£n = 8. AUC(0-t), area under the plasma
concentration-time curve from 0 to the time of the last quantifiable concentration; AUC, area under the plasma concentration-time curve from 0 to infinity; CL/F,
total apparent drug clearance; CLR, renal clearance; Cmax, maximum plasma concentration; Fe, fraction of dose excreted unchanged; Fu, ratio of unbound drug in
plasma; tmax, time to reach Cmax;t 1/2, terminal half-life; Vss/F, volume of distribution at steady state.
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Figure 2). Zibotentan clearance (CL/F) was decreased in
subjects with hepatic impairment with the magnitude of
decrease being related to the degree of hepatic impair-
ment (Figure 3). There was no statistical analysis of t1/2
values but the data demonstrated an increase in t1/2 in
subjects with hepatic impairment compared with sub-
jects with normal hepatic function (Table 3). The mag-
nitude of the increase in this parameter was related to
the degree of hepatic impairment. There was little dif-
ference in plasma protein binding between subjects with
normal and impaired hepatic function, thus changes in
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Figure 1 Zibotentan plasma concentration-time curves. Zibotentan plasma concentration-time curves for (a) subjects with normal hepatic
function and varying degrees of hepatic impairment and (b) subjects with normal renal function and varying degrees of renal impairment.
Tomkinson et al. BMC Clinical Pharmacology 2011, 11:3
http://www.biomedcentral.com/1472-6904/11/3
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groups were similar to changes in Cmax, AUC and CL/F
(Table 3).
Renal impairment study
The PK parameters and plasma concentrations of zibo-
tentan 10 mg in subjects with varying degrees of renal
impairment are presented in Table 3 and Figure 1b,
respectively. The results of the statistical analysis are
presented in Table 4 and Figure 2. Following a single
oral dose of zibotentan 10 mg, Cmax was unchanged in
subjects with mild, moderate and severe renal impair-
ment compared with subjects with normal renal func-
tion (Table 4). Exposure, in terms of AUC, was
significantly increased in subjects with renal impairment
and the magnitude of this increase was related to the
degree of renal impairment; AUC was 66%, 89%, and
117% higher, respectively, in subjects with mild, moder-
ate or severe renal impairment compared with subjects
with normal renal function (Table 4; Figure 2). Ziboten-
tan clearance (CL/F) decreased as the severity of renal
impairment increased, with mean CL/F being 39% and
44% lower in the moderate and severe renal impairment
groups, respectively, compared with subjects with nor-
mal renal function (Figure 4). Analysis of t1/2 indicated
a difference with degree of renal impairment, with
longer t1/2 values being observed as the severity of renal
impairment increased (Table 3). There was little differ-
ence in plasma protein binding between subjects with
normal and impaired renal function, thus changes in
free Cmax, free AUC and unbound CL/F across the
groups were similar to those observed for Cmax,A U C
and CL/F (Table 3).
Table 4 Ratios of pharmacokinetic parameters of zibotentan in subjects with varying degrees of renal impairment
compared with subjects with normal renal function, and in subjects with varying degrees of hepatic impairment
compared with subjects with normal hepatic function
Degree of hepatic impairment* Degree of renal impairment
†
PK parameter Mild Moderate Severe Mild Moderate Severe
Cmax ratio (90% CI) 0.93 (0.75-1.15) 0.89 (0.72-1.10) 0.95 (0.77-1.17) 1.07 (0.97-1.19) 1.09 (0.96-1.24) 1.12 (0.96-1.30)
AUC ratio (90% CI) 1.40 (0.91-2.17) 1.45 (0.94-2.24) 2.90 (1.88-4.49) 1.66 (1.38-1.99) 1.89 (1.50-2.39) 2.17 (1.64-2.86)
t1/2 difference, h (90% CI) - - - 1.87 (0.06-3.68)** 2.37 (0.08-4.66)** 2.87 (0.1-5.64)**
*Point estimate of geometric mean ratio in relation to control;
†Point estimate of geometric least squares ratio in relation to control; **Least squares mean
difference in relation to control; AUC, area under the plasma concentration-time curve from zero to infinity; Cmax, maximum plasma concentration; t1/2, terminal
half-life; CI = confidence interval.
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Figure 2 Forest plot of the ratios of zibotentan exposure. Forest plot of the ratios of zibotentan exposure (AUC) in subjects with varying
degrees of renal impairment compared with subjects with normal renal function, and in subjects with varying degrees of hepatic impairment
compared with subjects with normal hepatic function.
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Page 7 of 11Safety profile
Zibotentan was well tolerated in both studies and all
AEs were CTCAE Grade 1 or 2. Headache (seven sub-
jects [22%]) was the most common AE in the hepatic
study which was reported in at least one subject in all
groups, with the frequency increasing with the severity
of hepatic impairment (Table 5). Vomiting was the sec-
ond most common AE in the hepatic study, which was
reported in two (6%) subjects. One subject with moder-
ate hepatic impairment experienced a QT prolongation
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Figure 3 Box plot of zibotentan clearance in subjects with normal function and varying degrees of hepatic impairment.
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Figure 4 Scatter plot of zibotentan clearance versus actual creatinine clearance in subjects with normal renal function and varying
degrees of renal impairment.
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Page 8 of 11from 422 ms pre dose to 455 ms 4 hours post dose;
however, this event was not considered to be related to
zibotentan treatment and likely reflects normal variabil-
ity in this parameter.
Headache was also the most commonly reported AE in
the renal impairment study; however, the incidence of
headache did not appear to correlate with the severity of
renal impairment (Table 6). Other AEs reported in more
than two subjects included nasopharyngitis (n = 4), fati-
gue (n = 4), somnolence (n = 3) and nausea (n = 3).
In both studies, AEs of headache were assessed by
the investigator as being causally related to zibotentan
treatment, and either resolved without medication or
were managed with paracetamol. Minor reductions in
systolic and diastolic blood pressure were noted fol-
lowing zibotentan dosing in most subjects in both stu-
dies; however, these changes were not associated with
any symptoms and were not considered to be clinically
relevant. There were no deaths, serious AEs, disconti-
nuations due to AEs, or other significant AEs in either
study.
Discussion
A previous PK, metabolism and disposition study has
indicated that zibotentan and its metabolites are predo-
minately eliminated in urine. Between 71 and 94% of
dosed drug is eliminated in the urine with 58% of an
administered dose renally cleared as parent compound
[16]. In vitro investigations have demonstrated that
CYP3A4 is responsible for the metabolism of zibotentan
[17]. Furthermore, when zibotentan was administered in
combination with itraconazole, a potent inhibitor of
CYP3A4, AUC increased by 28% [17]. Consequently,
patients with hepatic or renal impairment may have
reduced clearance of zibotentan, which could potentially
lead to a greater exposure to zibotentan. A significant
proportion of patients with CRPC are likely to have
varying degrees of renal failure due to obstruction of the
urinary outflow tracts by the tumour [18] and as a con-
sequence of previous chemotherapy treatment regimens
[19]. These observations support an assessment of the
effects of hepatic or renal impairment on the PK of
zibotentan.
The PK parameters of zibotentan in normal healthy
subjects were similar between the two studies and were
consistent with the findings of previous PK studies [17].
In subjects with mild, moderate or severe hepatic or
renal impairment, there was no significant difference in
the Cmax of zibotentan following a single oral dose of
zibotentan 10 mg compared with those subjects with
normal organ function, indicating that absorption of the
drug was unchanged. Hepatic or renal impairment did,
however, significantly increase zibotentan exposure
(AUC), as a consequence of slower clearance of ziboten-
tan. Furthermore, exposure increased with degree of
hepatic or renal impairment. Of note, in the hepatic
impairment study, the PK profile of one subject in the
mild impairment group was similar to the PK profile of
subjects in the severe impairment group and therefore
the data from this subject will have influenced the mean
PK values for the mild group and contributed to the
wide variability observed (Figure 2). Indeed, when this
Table 5 AEs reported in >1 subject with normal hepatic function and varying degrees of hepatic impairment
Degree of hepatic impairment
Adverse event, n (%) Normal hepatic function (n = 8) Mild (n = 8) Moderate (n = 8) Severe (n = 8)
Any AE 1 (13) 1 (13) 3 (38) 4 (50)
Headache 1 (13) 1 (13) 2 (25) 3 (38)
Vomiting 1 (13) 0 0 1 (13)
Table 6 AEs reported in >1 subject with normal renal function and varying degrees of renal impairment
Degree of renal impairment
Adverse event, n (%) Normal renal function (n = 18) Mild (n = 12) Moderate (n = 9) Severe (n = 9)
Any AE 14 (78) 7 (58) 8 (89) 7 (78)
Headache 14 (78) 6 (50) 5 (56) 4 (44)
Nasopharyngitis 1 (6) 1 (8) 2 (22) 0
Fatigue 0 1 (8) 1 (11) 2 (22)
Somnolence 2 (11) 1 (8) 0 0
Nausea 1 (6) 1 (8) 0 1 (11)
Neck pain 0 2 (17) 0 0
Back pain 1 (6) 1 (8) 0 0
Dizziness 0 0 2 (22) 0
Dyspepsia 1 (6) 0 0 1 (11)
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Page 9 of 11subject was removed from the analysis, the upper confi-
dence limit of the AUC treatment ratio fell below the
predefined limit of 2. In both studies there was an
increase in the elimination half-life of zibotentan as the
degree of hepatic or renal impairment increased,
although this was more evident in subjects with hepatic
impairment. Hepatic and renal dysfunction has been
shown to cause changes in plasma protein binding,
therefore the fraction of unbound zibotentan was calcu-
l a t e da t3h o u r sp o s td o s et od e t e r m i n ef r e eC max,f r e e
AUC and unbound CL/F. Little change was documented
in protein binding across the groups in either study, and
consequently changes in free Cmax,f r e eA U Ca n d
unbound CL/F across the groups were similar to
changes in Cmax, AUC and CL/F.
Data from the hepatic study have demonstrated that
although mild and moderate impairment had only a
small impact on the average PK profile of zibotentan,
the impact of severe hepatic impairment was much
greater. Total plasma clearance of zibotentan in indivi-
duals with severe hepatic impairment was 64% lower
than that in individuals with normal function (Figure 3),
resulting in an approximate 190% increase in exposure
to zibotentan. Across the three hepatically impaired
groups there was a large amount of variability. Although
the average increase in exposure was 40 to 45% for the
mild and moderately impaired groups, increases of more
than 2 could not be ruled out. For the severely impaired
group, increases of 4.5 fold could not be ruled out. Data
from the renal study have shown that mild renal impair-
ment had only a small impact on the PK profile of zibo-
tentan with average exposure increasing 66% and the
upper CI remaining below 2, whereas, in this case, the
impact of moderate and severe renal impairment was
progressively greater. Total plasma clearance of ziboten-
tan in individuals with a moderate or severe degree of
renal impairment was 39% and 44% lower, respectively,
than in subjects with normal renal function, resulting in
increases in zibotentan exposure of 89% and 117%,
respectively.
In a Phase II study of zibotentan in patients with
metastatic CRPC and bone metastases, zibotentan 15
mg was well tolerated, with headache being the most
commonly reported AE [31]. Patients with mild renal
impairment who receive zibotentan 10 mg may have
exposures equivalent to those in patients receiving
zibotentan 15 mg in the Phase II study, and therefore
zibotentan is likely to be well tolerated. In contrast, in
a Phase I study of patients with metastatic CRPC,
patients taking zibotentan 22.5 mg reported dose-limit-
ing toxicities of Grade 3 peripheral edema and intra-
ventricular hemorrhage [30]. The most common AEs
reported in this study were headache, peripheral
edema, fatigue, nasal congestion, arthralgia and nausea.
Groups of patients who get more than a doubling in
mean drug plasma concentrations compared with nor-
mal patients could therefore be exposed to greater
risks with zibotentan therapy. As such, caution and
careful monitoring may be required if considering
using zibotentan 10 mg/day in patients with hepatic
insufficiency or moderate or severe renal insufficiency.
A single oral dose of zibotentan 10 mg was generally
well tolerated in subjects with normal renal and hepatic
function, and in those subjects with mild, moderate or
severe hepatic or renal impairment. The most com-
monly reported AE in both studies was headache, which
is consistent with reports from previous studies of zibo-
tentan and other endothelin receptor antagonists
[31,32]. The occurrence of headache increased with the
degree of hepatic impairment, but not with the degree
of renal impairment, where the incidence of headache
was highest in subjects with normal renal function. In
both studies, headache was reported to resolve without
medication or was managed with paracetamol. Overall,
there was an increase in the total number of AEs
reported as the severity of hepatic impairment increased;
13% and 50% of subjects experienced AEs in the normal
and severe hepatic impairment groups, respectively. In
contrast, in the renal impairment study, the number of
AEs reported was similar across all groups. This finding
suggests that the increased exposure to zibotentan in
subjects with moderate or severe renal impairment had
little effect on the tolerability of zibotentan.
Conclusions
Following administration of a single oral dose of ziboten-
tan 10 mg to subjects with hepatic or renal impairment,
the Cmax of zibotentan was unchanged, although ziboten-
tan exposure (AUC) was higher in subjects with hepatic or
renal impairment as a consequence of slower clearance of
zibotentan. The magnitude of the increase in exposure
was related to the degree of hepatic or renal impairment.
Despite this increased exposure, there were no differences
i nt h et y p eo rs e v e r i t yo fA E s .Z i b o t e n t a n1 0m gi sc u r -
rently undergoing further clinical investigation in patients
with CRPC in a large Phase III clinical programme [11].
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